This pipeline uses various statistical tests to identify miRs whose log2 expression levels correlated to selected clinical features.
Testing the association between 542 miRs and 43 clinical features across 200 samples, statistically thresholded by P value < 0.05 and Q value < 0.3, 14 clinical features related to at least one miRs.
-
5 miRs correlated to 'Time to Death'.
-
HSA-MIR-23B , HSA-MIR-502 , HSA-MIR-532 , HSA-MIR-361 , HSA-MIR-549
-
7 miRs correlated to 'AGE'.
-
HSA-MIR-424 , HSA-MIR-1-2 , HSA-MIR-204 , HSA-MIR-1468 , HSA-MIR-503 , ...
-
32 miRs correlated to 'HISTOLOGICAL.TYPE'.
-
HSA-MIR-205 , HSA-MIR-944 , HSA-MIR-375 , HSA-MIR-194-2 , HSA-MIR-10A , ...
-
45 miRs correlated to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
-
HSA-MIR-19A , HSA-MIR-660 , HSA-MIR-20A , HSA-MIR-143 , HSA-MIR-19B-2 , ...
-
1 miR correlated to 'RACE'.
-
HSA-MIR-3130-1
-
1 miR correlated to 'ETHNICITY'.
-
HSA-MIR-140
-
3 miRs correlated to 'WEIGHT_KG_AT_DIAGNOSIS'.
-
HSA-MIR-3190 , HSA-MIR-766 , HSA-MIR-1908
-
4 miRs correlated to 'TUMOR_SAMPLE_PROCUREMENT_COUNTRY'.
-
HSA-MIR-550A-2 , HSA-MIR-215 , HSA-MIR-1274B , HSA-MIR-3130-1
-
1 miR correlated to 'PATIENT.AGEBEGANSMOKINGINYEARS'.
-
HSA-MIR-18A
-
28 miRs correlated to 'RADIATION_THERAPY_TYPE'.
-
HSA-MIR-19A , HSA-MIR-143 , HSA-MIR-212 , HSA-MIR-19B-2 , HSA-MIR-20A , ...
-
5 miRs correlated to 'MENOPAUSE_STATUS'.
-
HSA-MIR-125B-2 , HSA-MIR-99A , HSA-LET-7C , HSA-MIR-424 , HSA-MIR-503
-
3 miRs correlated to 'KERATINIZATION_SQUAMOUS_CELL'.
-
HSA-MIR-152 , HSA-MIR-23C , HSA-MIR-191
-
37 miRs correlated to 'INITIAL_PATHOLOGIC_DX_YEAR'.
-
HSA-MIR-24-2 , HSA-MIR-212 , HSA-MIR-98 , HSA-MIR-660 , HSA-MIR-143 , ...
-
7 miRs correlated to 'AGE_AT_DIAGNOSIS'.
-
HSA-MIR-424 , HSA-MIR-1-2 , HSA-MIR-204 , HSA-MIR-1468 , HSA-MIR-503 , ...
-
No miRs correlated to 'PATHOLOGY.T.STAGE', 'PATHOLOGY.N.STAGE', 'PATHOLOGY.M.STAGE', 'NUMBERPACKYEARSSMOKED', 'NUMBER.OF.LYMPH.NODES', 'TUMOR_STATUS', 'NEOPLASMHISTOLOGICGRADE', 'TOBACCO_SMOKING_YEAR_STOPPED', 'TOBACCO_SMOKING_PACK_YEARS_SMOKED', 'TOBACCO_SMOKING_HISTORY', 'RADIATION_ADJUVANT_UNITS', 'PREGNANCIES_COUNT_TOTAL', 'PREGNANCIES_COUNT_STILLBIRTH', 'PATIENT.PATIENTPREGNANCYSPONTANEOUSABORTIONCOUNT', 'PREGNANCIES_COUNT_LIVE_BIRTH', 'PATIENT.PATIENTPREGNANCYTHERAPEUTICABORTIONCOUNT', 'PREGNANCIES_COUNT_ECTOPIC', 'LYMPH_NODE_LOCATION', 'LOCATION_OF_POSITIVE_MARGINS', 'LYMPHOVASCULAR_INVOLVEMENT', 'LYMPH_NODES_EXAMINED_HE_COUNT', 'LYMPH_NODES_EXAMINED', 'HYSTERECTOMY_TYPE', 'HISTORY_HORMONAL_CONTRACEPTIVES_USE', 'HEIGHT_CM_AT_DIAGNOSIS', 'CORPUS_INVOLVEMENT', 'CHEMO_CONCURRENT_TYPE', 'CERVIX_SUV_RESULTS', and 'AJCC_TUMOR_PATHOLOGIC_PT'.
Complete statistical result table is provided in Supplement Table 1
Table 1. Get Full Table This table shows the clinical features, statistical methods used, and the number of miRs that are significantly associated with each clinical feature at P value < 0.05 and Q value < 0.3.
Clinical feature | Statistical test | Significant miRs | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=5 | shorter survival | N=1 | longer survival | N=4 |
AGE | Spearman correlation test | N=7 | older | N=3 | younger | N=4 |
PATHOLOGY T STAGE | Spearman correlation test | N=0 | ||||
PATHOLOGY N STAGE | Wilcoxon test | N=0 | ||||
PATHOLOGY M STAGE | Kruskal-Wallis test | N=0 | ||||
HISTOLOGICAL TYPE | Kruskal-Wallis test | N=32 | ||||
RADIATIONS RADIATION REGIMENINDICATION | Wilcoxon test | N=45 | yes | N=45 | no | N=0 |
NUMBERPACKYEARSSMOKED | Spearman correlation test | N=0 | ||||
NUMBER OF LYMPH NODES | Spearman correlation test | N=0 | ||||
RACE | Kruskal-Wallis test | N=1 | ||||
ETHNICITY | Wilcoxon test | N=1 | not hispanic or latino | N=1 | hispanic or latino | N=0 |
WEIGHT_KG_AT_DIAGNOSIS | Spearman correlation test | N=3 | higher weight_kg_at_diagnosis | N=3 | lower weight_kg_at_diagnosis | N=0 |
TUMOR_STATUS | Wilcoxon test | N=0 | ||||
TUMOR_SAMPLE_PROCUREMENT_COUNTRY | Kruskal-Wallis test | N=4 | ||||
NEOPLASMHISTOLOGICGRADE | Kruskal-Wallis test | N=0 | ||||
TOBACCO_SMOKING_YEAR_STOPPED | Spearman correlation test | N=0 | ||||
TOBACCO_SMOKING_PACK_YEARS_SMOKED | Spearman correlation test | N=0 | ||||
TOBACCO_SMOKING_HISTORY | Kruskal-Wallis test | N=0 | ||||
PATIENT AGEBEGANSMOKINGINYEARS | Spearman correlation test | N=1 | higher patient.agebegansmokinginyears | N=0 | lower patient.agebegansmokinginyears | N=1 |
RADIATION_THERAPY_TYPE | Kruskal-Wallis test | N=28 | ||||
RADIATION_ADJUVANT_UNITS | Wilcoxon test | N=0 | ||||
PREGNANCIES_COUNT_TOTAL | Spearman correlation test | N=0 | ||||
PREGNANCIES_COUNT_STILLBIRTH | Spearman correlation test | N=0 | ||||
PATIENT PATIENTPREGNANCYSPONTANEOUSABORTIONCOUNT | Spearman correlation test | N=0 | ||||
PREGNANCIES_COUNT_LIVE_BIRTH | Spearman correlation test | N=0 | ||||
PATIENT PATIENTPREGNANCYTHERAPEUTICABORTIONCOUNT | Spearman correlation test | N=0 | ||||
PREGNANCIES_COUNT_ECTOPIC | Spearman correlation test | N=0 | ||||
LYMPH_NODE_LOCATION | Kruskal-Wallis test | N=0 | ||||
LOCATION_OF_POSITIVE_MARGINS | Kruskal-Wallis test | N=0 | ||||
MENOPAUSE_STATUS | Kruskal-Wallis test | N=5 | ||||
LYMPHOVASCULAR_INVOLVEMENT | Wilcoxon test | N=0 | ||||
LYMPH_NODES_EXAMINED_HE_COUNT | Spearman correlation test | N=0 | ||||
LYMPH_NODES_EXAMINED | Spearman correlation test | N=0 | ||||
KERATINIZATION_SQUAMOUS_CELL | Wilcoxon test | N=3 | non-keratinizing squamous cell carcinoma | N=3 | keratinizing squamous cell carcinoma | N=0 |
INITIAL_PATHOLOGIC_DX_YEAR | Spearman correlation test | N=37 | higher initial_pathologic_dx_year | N=11 | lower initial_pathologic_dx_year | N=26 |
HYSTERECTOMY_TYPE | Kruskal-Wallis test | N=0 | ||||
HISTORY_HORMONAL_CONTRACEPTIVES_USE | Kruskal-Wallis test | N=0 | ||||
HEIGHT_CM_AT_DIAGNOSIS | Spearman correlation test | N=0 | ||||
CORPUS_INVOLVEMENT | Wilcoxon test | N=0 | ||||
CHEMO_CONCURRENT_TYPE | Wilcoxon test | N=0 | ||||
CERVIX_SUV_RESULTS | Spearman correlation test | N=0 | ||||
AJCC_TUMOR_PATHOLOGIC_PT | Kruskal-Wallis test | N=0 | ||||
AGE_AT_DIAGNOSIS | Spearman correlation test | N=7 | higher age_at_diagnosis | N=3 | lower age_at_diagnosis | N=4 |
Table S1. Basic characteristics of clinical feature: 'Time to Death'
Time to Death | Duration (Months) | 0-182.9 (median=13.9) |
censored | N = 155 | |
death | N = 38 | |
Significant markers | N = 5 | |
associated with shorter survival | 1 | |
associated with longer survival | 4 |
Table S2. Get Full Table List of 5 miRs significantly associated with 'Time to Death' by Cox regression test
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
HSA-MIR-23B | 0.33 | 0.0001012 | 0.055 | 0.284 |
HSA-MIR-502 | 0.51 | 0.000119 | 0.064 | 0.285 |
HSA-MIR-532 | 0.39 | 0.0001451 | 0.078 | 0.315 |
HSA-MIR-361 | 0.27 | 0.0004949 | 0.27 | 0.313 |
HSA-MIR-549 | 1.59 | 0.0005262 | 0.28 | 0.742 |
Table S3. Basic characteristics of clinical feature: 'AGE'
AGE | Mean (SD) | 47.48 (13) |
Significant markers | N = 7 | |
pos. correlated | 3 | |
neg. correlated | 4 |
Table S4. Get Full Table List of 7 miRs significantly correlated to 'AGE' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-424 | -0.34 | 8.969e-07 | 0.000486 |
HSA-MIR-1-2 | 0.3151 | 6.12e-06 | 0.00331 |
HSA-MIR-204 | 0.2974 | 3.938e-05 | 0.0213 |
HSA-MIR-1468 | 0.2737 | 9.578e-05 | 0.0516 |
HSA-MIR-503 | -0.268 | 0.0001295 | 0.0696 |
HSA-MIR-455 | -0.2596 | 0.0002128 | 0.114 |
HSA-MIR-450B | -0.2524 | 0.0003217 | 0.172 |
Table S5. Basic characteristics of clinical feature: 'PATHOLOGY.T.STAGE'
PATHOLOGY.T.STAGE | Mean (SD) | 1.32 (0.57) |
N | ||
1 | 108 | |
2 | 39 | |
3 | 2 | |
4 | 2 | |
Significant markers | N = 0 |
Table S6. Basic characteristics of clinical feature: 'PATHOLOGY.N.STAGE'
PATHOLOGY.N.STAGE | Labels | N |
class0 | 100 | |
class1 | 44 | |
Significant markers | N = 0 |
Table S7. Basic characteristics of clinical feature: 'PATHOLOGY.M.STAGE'
PATHOLOGY.M.STAGE | Labels | N |
M0 | 83 | |
M1 | 4 | |
MX | 70 | |
Significant markers | N = 0 |
Table S8. Basic characteristics of clinical feature: 'HISTOLOGICAL.TYPE'
HISTOLOGICAL.TYPE | Labels | N |
ADENOSQUAMOUS | 2 | |
CERVICAL SQUAMOUS CELL CARCINOMA | 168 | |
ENDOCERVICAL ADENOCARCINOMA OF THE USUAL TYPE | 4 | |
ENDOCERVICAL TYPE OF ADENOCARCINOMA | 20 | |
ENDOMETRIOID ADENOCARCINOMA OF ENDOCERVIX | 2 | |
MUCINOUS ADENOCARCINOMA OF ENDOCERVICAL TYPE | 4 | |
Significant markers | N = 32 |
Table S9. Get Full Table List of top 10 miRs differentially expressed by 'HISTOLOGICAL.TYPE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-205 | 8.557e-14 | 4.64e-11 |
HSA-MIR-944 | 5.636e-13 | 3.05e-10 |
HSA-MIR-375 | 5.316e-12 | 2.87e-09 |
HSA-MIR-194-2 | 2.178e-10 | 1.17e-07 |
HSA-MIR-10A | 7.616e-10 | 4.1e-07 |
HSA-MIR-192 | 1.471e-09 | 7.9e-07 |
HSA-MIR-194-1 | 2.664e-09 | 1.43e-06 |
HSA-MIR-203 | 6.401e-09 | 3.42e-06 |
HSA-MIR-1293 | 2.181e-08 | 1.16e-05 |
HSA-MIR-27A | 6.506e-07 | 0.000347 |
45 miRs related to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
Table S10. Basic characteristics of clinical feature: 'RADIATIONS.RADIATION.REGIMENINDICATION'
RADIATIONS.RADIATION.REGIMENINDICATION | Labels | N |
NO | 32 | |
YES | 168 | |
Significant markers | N = 45 | |
Higher in YES | 45 | |
Higher in NO | 0 |
Table S11. Get Full Table List of top 10 miRs differentially expressed by 'RADIATIONS.RADIATION.REGIMENINDICATION'
W(pos if higher in 'YES') | wilcoxontestP | Q | AUC | |
---|---|---|---|---|
HSA-MIR-19A | 4465 | 3.218e-09 | 1.74e-06 | 0.8305 |
HSA-MIR-660 | 4445 | 4.815e-09 | 2.6e-06 | 0.8268 |
HSA-MIR-20A | 4434 | 5.999e-09 | 3.23e-06 | 0.8248 |
HSA-MIR-143 | 1002 | 1.945e-08 | 1.04e-05 | 0.8136 |
HSA-MIR-19B-2 | 4359 | 2.594e-08 | 1.39e-05 | 0.8108 |
HSA-MIR-15A | 4321 | 5.322e-08 | 2.85e-05 | 0.8038 |
HSA-MIR-93 | 4272 | 1.314e-07 | 7.02e-05 | 0.7946 |
HSA-MIR-362 | 4251 | 1.92e-07 | 0.000102 | 0.7907 |
HSA-MIR-338 | 4197 | 4.982e-07 | 0.000265 | 0.7807 |
HSA-MIR-616 | 4036 | 5.194e-07 | 0.000276 | 0.7843 |
Table S12. Basic characteristics of clinical feature: 'NUMBERPACKYEARSSMOKED'
NUMBERPACKYEARSSMOKED | Mean (SD) | 19.43 (14) |
Significant markers | N = 0 |
Table S13. Basic characteristics of clinical feature: 'NUMBER.OF.LYMPH.NODES'
NUMBER.OF.LYMPH.NODES | Mean (SD) | 1.07 (2.6) |
Significant markers | N = 0 |
Table S14. Basic characteristics of clinical feature: 'RACE'
RACE | Labels | N |
AMERICAN INDIAN OR ALASKA NATIVE | 7 | |
ASIAN | 16 | |
BLACK OR AFRICAN AMERICAN | 23 | |
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 1 | |
WHITE | 148 | |
Significant markers | N = 1 |
Table S15. Get Full Table List of one miR differentially expressed by 'RACE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-3130-1 | 0.0004338 | 0.235 |
Table S16. Basic characteristics of clinical feature: 'ETHNICITY'
ETHNICITY | Labels | N |
HISPANIC OR LATINO | 13 | |
NOT HISPANIC OR LATINO | 144 | |
Significant markers | N = 1 | |
Higher in NOT HISPANIC OR LATINO | 1 | |
Higher in HISPANIC OR LATINO | 0 |
Table S17. Get Full Table List of one miR differentially expressed by 'ETHNICITY'
W(pos if higher in 'NOT HISPANIC OR LATINO') | wilcoxontestP | Q | AUC | |
---|---|---|---|---|
HSA-MIR-140 | c("1488", "0.0004434") | c("1488", "0.0004434") | 0.238 | 0.7949 |
Table S18. Basic characteristics of clinical feature: 'WEIGHT_KG_AT_DIAGNOSIS'
WEIGHT_KG_AT_DIAGNOSIS | Mean (SD) | 75.21 (21) |
Significant markers | N = 3 | |
pos. correlated | 3 | |
neg. correlated | 0 |
Table S19. Get Full Table List of 3 miRs significantly correlated to 'WEIGHT_KG_AT_DIAGNOSIS' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-3190 | 0.4355 | 6.05e-05 | 0.0328 |
HSA-MIR-766 | 0.2753 | 0.0001687 | 0.0913 |
HSA-MIR-1908 | 0.4292 | 0.0004024 | 0.217 |
Table S20. Basic characteristics of clinical feature: 'TUMOR_STATUS'
TUMOR_STATUS | Labels | N |
TUMOR FREE | 51 | |
WITH TUMOR | 22 | |
Significant markers | N = 0 |
4 miRs related to 'TUMOR_SAMPLE_PROCUREMENT_COUNTRY'.
Table S21. Basic characteristics of clinical feature: 'TUMOR_SAMPLE_PROCUREMENT_COUNTRY'
TUMOR_SAMPLE_PROCUREMENT_COUNTRY | Labels | N |
NIGERIA | 1 | |
RUSSIA | 11 | |
UKRAINE | 7 | |
UNITED STATES | 169 | |
VIETNAM | 12 | |
Significant markers | N = 4 |
Table S22. Get Full Table List of 4 miRs differentially expressed by 'TUMOR_SAMPLE_PROCUREMENT_COUNTRY'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-550A-2 | 9.909e-05 | 0.0537 |
HSA-MIR-215 | 0.000201 | 0.109 |
HSA-MIR-1274B | 0.0002179 | 0.118 |
HSA-MIR-3130-1 | 0.0002286 | 0.123 |
Table S23. Basic characteristics of clinical feature: 'NEOPLASMHISTOLOGICGRADE'
NEOPLASMHISTOLOGICGRADE | Labels | N |
G1 | 14 | |
G2 | 94 | |
G3 | 83 | |
G4 | 1 | |
GX | 5 | |
Significant markers | N = 0 |
No miR related to 'TOBACCO_SMOKING_YEAR_STOPPED'.
Table S24. Basic characteristics of clinical feature: 'TOBACCO_SMOKING_YEAR_STOPPED'
TOBACCO_SMOKING_YEAR_STOPPED | Mean (SD) | 1998.37 (12) |
Significant markers | N = 0 |
No miR related to 'TOBACCO_SMOKING_PACK_YEARS_SMOKED'.
Table S25. Basic characteristics of clinical feature: 'TOBACCO_SMOKING_PACK_YEARS_SMOKED'
TOBACCO_SMOKING_PACK_YEARS_SMOKED | Mean (SD) | 19.43 (14) |
Significant markers | N = 0 |
Table S26. Basic characteristics of clinical feature: 'TOBACCO_SMOKING_HISTORY'
TOBACCO_SMOKING_HISTORY | Labels | N |
CURRENT REFORMED SMOKER FOR < OR = 15 YEARS | 25 | |
CURRENT REFORMED SMOKER FOR > 15 YEARS | 8 | |
CURRENT REFORMED SMOKER, DURATION NOT SPECIFIED | 3 | |
CURRENT SMOKER | 43 | |
LIFELONG NON-SMOKER | 89 | |
Significant markers | N = 0 |
One miR related to 'PATIENT.AGEBEGANSMOKINGINYEARS'.
Table S27. Basic characteristics of clinical feature: 'PATIENT.AGEBEGANSMOKINGINYEARS'
PATIENT.AGEBEGANSMOKINGINYEARS | Mean (SD) | 20.46 (6.2) |
Significant markers | N = 1 | |
pos. correlated | 0 | |
neg. correlated | 1 |
Table S28. Get Full Table List of one miR significantly correlated to 'PATIENT.AGEBEGANSMOKINGINYEARS' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-18A | -0.4617 | 0.0004406 | 0.239 |
Table S29. Basic characteristics of clinical feature: 'RADIATION_THERAPY_TYPE'
RADIATION_THERAPY_TYPE | Labels | N |
COMBINATION | 18 | |
EXTERNAL | 44 | |
EXTERNAL BEAM | 14 | |
IMPLANTS | 1 | |
INTERNAL | 8 | |
Significant markers | N = 28 |
Table S30. Get Full Table List of top 10 miRs differentially expressed by 'RADIATION_THERAPY_TYPE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-19A | 3.716e-07 | 0.000201 |
HSA-MIR-143 | 6.778e-07 | 0.000367 |
HSA-MIR-212 | 1.719e-06 | 0.000928 |
HSA-MIR-19B-2 | 2.156e-06 | 0.00116 |
HSA-MIR-20A | 2.466e-06 | 0.00133 |
HSA-MIR-616 | 3.051e-06 | 0.00164 |
HSA-MIR-660 | 4.142e-06 | 0.00222 |
HSA-MIR-326 | 8.391e-06 | 0.00449 |
HSA-MIR-301A | 1.056e-05 | 0.00564 |
HSA-MIR-1274B | 1.38e-05 | 0.00735 |
Table S31. Basic characteristics of clinical feature: 'RADIATION_ADJUVANT_UNITS'
RADIATION_ADJUVANT_UNITS | Labels | N |
CGY | 16 | |
GY | 4 | |
Significant markers | N = 0 |
Table S32. Basic characteristics of clinical feature: 'PREGNANCIES_COUNT_TOTAL'
PREGNANCIES_COUNT_TOTAL | Mean (SD) | 3.49 (2.4) |
Significant markers | N = 0 |
No miR related to 'PREGNANCIES_COUNT_STILLBIRTH'.
Table S33. Basic characteristics of clinical feature: 'PREGNANCIES_COUNT_STILLBIRTH'
PREGNANCIES_COUNT_STILLBIRTH | Mean (SD) | 0.08 (0.37) |
Value | N | |
0 | 94 | |
1 | 5 | |
3 | 1 | |
Significant markers | N = 0 |
No miR related to 'PATIENT.PATIENTPREGNANCYSPONTANEOUSABORTIONCOUNT'.
Table S34. Basic characteristics of clinical feature: 'PATIENT.PATIENTPREGNANCYSPONTANEOUSABORTIONCOUNT'
PATIENT.PATIENTPREGNANCYSPONTANEOUSABORTIONCOUNT | Mean (SD) | 0.35 (0.59) |
Value | N | |
0 | 81 | |
1 | 30 | |
2 | 4 | |
3 | 1 | |
Significant markers | N = 0 |
No miR related to 'PREGNANCIES_COUNT_LIVE_BIRTH'.
Table S35. Basic characteristics of clinical feature: 'PREGNANCIES_COUNT_LIVE_BIRTH'
PREGNANCIES_COUNT_LIVE_BIRTH | Mean (SD) | 2.47 (1.8) |
Significant markers | N = 0 |
No miR related to 'PATIENT.PATIENTPREGNANCYTHERAPEUTICABORTIONCOUNT'.
Table S36. Basic characteristics of clinical feature: 'PATIENT.PATIENTPREGNANCYTHERAPEUTICABORTIONCOUNT'
PATIENT.PATIENTPREGNANCYTHERAPEUTICABORTIONCOUNT | Mean (SD) | 0.91 (1.9) |
Significant markers | N = 0 |
Table S37. Basic characteristics of clinical feature: 'PREGNANCIES_COUNT_ECTOPIC'
PREGNANCIES_COUNT_ECTOPIC | Mean (SD) | 0.1 (0.33) |
Value | N | |
0 | 92 | |
1 | 8 | |
2 | 1 | |
Significant markers | N = 0 |
Table S38. Basic characteristics of clinical feature: 'LYMPH_NODE_LOCATION'
LYMPH_NODE_LOCATION | Labels | N |
2003 | 1 | |
2010 | 1 | |
COMMON ILIAC | 1 | |
PELVIC (EXTERNAL ILIAC, INTERNAL ILIAC, OBTURATOR) | 41 | |
Significant markers | N = 0 |
No miR related to 'LOCATION_OF_POSITIVE_MARGINS'.
Table S39. Basic characteristics of clinical feature: 'LOCATION_OF_POSITIVE_MARGINS'
LOCATION_OF_POSITIVE_MARGINS | Labels | N |
MACROSCOPIC PARAMETRIAL INVOLVEMENT | 2 | |
MICROSCOPIC PARAMETRIAL INVOLVEMENT | 7 | |
OTHER LOCATION, SPECIFY | 13 | |
POSITIVE BLADDER MARGIN | 1 | |
POSITIVE VAGINAL MARGIN | 6 | |
Significant markers | N = 0 |
Table S40. Basic characteristics of clinical feature: 'MENOPAUSE_STATUS'
MENOPAUSE_STATUS | Labels | N |
INDETERMINATE (NEITHER PRE OR POSTMENOPAUSAL) | 2 | |
PERI (6-12 MONTHS SINCE LAST MENSTRUAL PERIOD) | 10 | |
POST (PRIOR BILATERAL OVARIECTOMY OR >12 MO SINCE LMP WITH NO PRIOR HYSTERECTOMY) | 58 | |
PRE (<6 MONTHS SINCE LMP AND NO PRIOR BILATERAL OVARIECTOMY AND NOT ON ESTROGEN REPLACEMENT) | 85 | |
Significant markers | N = 5 |
Table S41. Get Full Table List of 5 miRs differentially expressed by 'MENOPAUSE_STATUS'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-125B-2 | 6.767e-05 | 0.0367 |
HSA-MIR-99A | 9.278e-05 | 0.0502 |
HSA-LET-7C | 0.0001179 | 0.0637 |
HSA-MIR-424 | 0.0001447 | 0.078 |
HSA-MIR-503 | 0.0003396 | 0.183 |
Table S42. Basic characteristics of clinical feature: 'LYMPHOVASCULAR_INVOLVEMENT'
LYMPHOVASCULAR_INVOLVEMENT | Labels | N |
ABSENT | 56 | |
PRESENT | 66 | |
Significant markers | N = 0 |
No miR related to 'LYMPH_NODES_EXAMINED_HE_COUNT'.
Table S43. Basic characteristics of clinical feature: 'LYMPH_NODES_EXAMINED_HE_COUNT'
LYMPH_NODES_EXAMINED_HE_COUNT | Mean (SD) | 1.07 (2.6) |
Significant markers | N = 0 |
Table S44. Basic characteristics of clinical feature: 'LYMPH_NODES_EXAMINED'
LYMPH_NODES_EXAMINED | Mean (SD) | 22.39 (13) |
Significant markers | N = 0 |
3 miRs related to 'KERATINIZATION_SQUAMOUS_CELL'.
Table S45. Basic characteristics of clinical feature: 'KERATINIZATION_SQUAMOUS_CELL'
KERATINIZATION_SQUAMOUS_CELL | Labels | N |
KERATINIZING SQUAMOUS CELL CARCINOMA | 43 | |
NON-KERATINIZING SQUAMOUS CELL CARCINOMA | 88 | |
Significant markers | N = 3 | |
Higher in NON-KERATINIZING SQUAMOUS CELL CARCINOMA | 3 | |
Higher in KERATINIZING SQUAMOUS CELL CARCINOMA | 0 |
Table S46. Get Full Table List of 3 miRs differentially expressed by 'KERATINIZATION_SQUAMOUS_CELL'
W(pos if higher in 'NON-KERATINIZING SQUAMOUS CELL CARCINOMA') | wilcoxontestP | Q | AUC | |
---|---|---|---|---|
HSA-MIR-152 | 1162 | 0.0003494 | 0.189 | 0.6929 |
HSA-MIR-23C | 866 | 0.0003711 | 0.201 | 0.7039 |
HSA-MIR-191 | 2607 | 0.0004616 | 0.249 | 0.689 |
37 miRs related to 'INITIAL_PATHOLOGIC_DX_YEAR'.
Table S47. Basic characteristics of clinical feature: 'INITIAL_PATHOLOGIC_DX_YEAR'
INITIAL_PATHOLOGIC_DX_YEAR | Mean (SD) | 2007.28 (5.2) |
Significant markers | N = 37 | |
pos. correlated | 11 | |
neg. correlated | 26 |
Table S48. Get Full Table List of top 10 miRs significantly correlated to 'INITIAL_PATHOLOGIC_DX_YEAR' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-24-2 | -0.4102 | 1.622e-09 | 8.79e-07 |
HSA-MIR-212 | -0.4055 | 2.572e-09 | 1.39e-06 |
HSA-MIR-98 | -0.3803 | 2.779e-08 | 1.5e-05 |
HSA-MIR-660 | 0.3739 | 4.938e-08 | 2.66e-05 |
HSA-MIR-143 | -0.3681 | 8.216e-08 | 4.42e-05 |
HSA-MIR-152 | -0.346 | 5.219e-07 | 0.00028 |
HSA-MIR-15A | 0.3289 | 1.984e-06 | 0.00106 |
HSA-MIR-1274B | -0.3302 | 2.022e-06 | 0.00108 |
HSA-MIR-19A | 0.3244 | 2.78e-06 | 0.00148 |
HSA-MIR-326 | -0.3222 | 3.902e-06 | 0.00208 |
Table S49. Basic characteristics of clinical feature: 'HYSTERECTOMY_TYPE'
HYSTERECTOMY_TYPE | Labels | N |
OTHER | 3 | |
RADICAL HYSTERECTOMY | 129 | |
SIMPLE HYSTERECTOMY | 5 | |
Significant markers | N = 0 |
No miR related to 'HISTORY_HORMONAL_CONTRACEPTIVES_USE'.
Table S50. Basic characteristics of clinical feature: 'HISTORY_HORMONAL_CONTRACEPTIVES_USE'
HISTORY_HORMONAL_CONTRACEPTIVES_USE | Labels | N |
CURRENT USER | 8 | |
FORMER USER | 40 | |
NEVER USED | 47 | |
Significant markers | N = 0 |
Table S51. Basic characteristics of clinical feature: 'HEIGHT_CM_AT_DIAGNOSIS'
HEIGHT_CM_AT_DIAGNOSIS | Mean (SD) | 162.09 (7.2) |
Significant markers | N = 0 |
Table S52. Basic characteristics of clinical feature: 'CORPUS_INVOLVEMENT'
CORPUS_INVOLVEMENT | Labels | N |
ABSENT | 81 | |
PRESENT | 15 | |
Significant markers | N = 0 |
Table S53. Basic characteristics of clinical feature: 'CHEMO_CONCURRENT_TYPE'
CHEMO_CONCURRENT_TYPE | Labels | N |
CARBOPLATIN | 3 | |
CISPLATIN | 17 | |
Significant markers | N = 0 |
Table S54. Basic characteristics of clinical feature: 'CERVIX_SUV_RESULTS'
CERVIX_SUV_RESULTS | Mean (SD) | 12.84 (6.1) |
Significant markers | N = 0 |
Table S55. Basic characteristics of clinical feature: 'AJCC_TUMOR_PATHOLOGIC_PT'
AJCC_TUMOR_PATHOLOGIC_PT | Labels | N |
T1A | 2 | |
T1A1 | 1 | |
T1B | 26 | |
T1B1 | 55 | |
T1B2 | 24 | |
T2 | 3 | |
T2A | 6 | |
T2A1 | 7 | |
T2A2 | 9 | |
T2B | 14 | |
T3B | 2 | |
T4 | 2 | |
TIS | 1 | |
TX | 8 | |
Significant markers | N = 0 |
Table S56. Basic characteristics of clinical feature: 'AGE_AT_DIAGNOSIS'
AGE_AT_DIAGNOSIS | Mean (SD) | 47.55 (13) |
Significant markers | N = 7 | |
pos. correlated | 3 | |
neg. correlated | 4 |
Table S57. Get Full Table List of 7 miRs significantly correlated to 'AGE_AT_DIAGNOSIS' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-424 | -0.3444 | 5.916e-07 | 0.000321 |
HSA-MIR-1-2 | 0.3178 | 4.791e-06 | 0.00259 |
HSA-MIR-204 | 0.3018 | 2.833e-05 | 0.0153 |
HSA-MIR-1468 | 0.2772 | 7.358e-05 | 0.0397 |
HSA-MIR-503 | -0.2721 | 9.692e-05 | 0.0521 |
HSA-MIR-450B | -0.2568 | 0.0002424 | 0.13 |
HSA-MIR-455 | -0.248 | 0.0003997 | 0.214 |
-
Expresson data file = CESC-TP.miRseq_RPKM_log2.txt
-
Clinical data file = CESC-TP.merged_data.txt
-
Number of patients = 200
-
Number of miRs = 542
-
Number of clinical features = 43
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.